R&G PharmaStudies Co., Ltd. (SHE:301333)
China flag China · Delayed Price · Currency is CNY
60.81
-1.49 (-2.39%)
At close: May 12, 2026

R&G PharmaStudies Ratios and Metrics

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
May '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
5,9805,6664,7566,1904,940-
Market Cap Growth
36.50%19.12%-23.17%25.30%--
Enterprise Value
4,3113,9603,1244,5643,498-
Last Close Price
62.3059.5549.8363.8950.84-
PE Ratio
44.4541.3933.9238.0943.55-
Forward PE
36.0133.1325.30---
PS Ratio
6.676.666.398.587.75-
PB Ratio
2.982.872.593.533.10-
P/TBV Ratio
3.163.042.753.583.14-
P/FCF Ratio
67.5559.6835.2935.8545.06-
P/OCF Ratio
55.7249.6130.7332.1537.87-
EV/Sales Ratio
4.814.654.206.335.49-
EV/EBITDA Ratio
30.6030.6221.6429.6931.68-
EV/EBIT Ratio
34.5832.3225.8134.8133.97-
EV/FCF Ratio
48.7041.7223.1826.4331.90-
Debt / Equity Ratio
0.020.010.040.010.010.03
Debt / EBITDA Ratio
0.300.130.460.050.130.08
Debt / FCF Ratio
0.480.190.530.050.140.14
Net Debt / Equity Ratio
-0.84-0.88-0.93-0.97-0.94-0.80
Net Debt / EBITDA Ratio
-13.16-13.38-11.81-11.03-13.64-2.59
Net Debt / FCF Ratio
-18.94-18.22-12.65-9.82-13.74-4.60
Asset Turnover
0.380.360.340.370.501.01
Inventory Turnover
9.478.948.048.338.3610.43
Quick Ratio
5.835.444.736.206.252.35
Current Ratio
6.015.604.886.386.452.58
Return on Equity (ROE)
6.96%7.26%7.90%9.73%11.24%25.91%
Return on Assets (ROA)
3.33%3.23%3.43%4.14%5.03%11.35%
Return on Invested Capital (ROIC)
38.63%57.84%113.70%159.47%104.63%136.45%
Return on Capital Employed (ROCE)
6.10%6.10%6.40%7.50%6.40%24.60%
Earnings Yield
2.23%2.42%2.95%2.63%2.30%-
FCF Yield
1.48%1.68%2.83%2.79%2.22%-
Dividend Yield
0.26%0.27%0.32%0.31%0.31%-
Payout Ratio
12.56%8.61%20.24%3.58%--
Buyback Yield / Dilution
0.16%-0.36%0.64%-16.78%-14.43%0.38%
Total Shareholder Return
0.42%-0.09%0.96%-16.46%-14.12%0.38%
Source: S&P Global Market Intelligence. Standard template. Financial Sources.